LYEL:NASDAQLyell Immunopharma, Inc. Analysis
Data as of 2026-08-25 - not real-time
$15.45
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Lyell Immunopharma, Inc. is priced at $15.45, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 15.3%. With RSI at 57.5 the momentum picture is neutral, alongside a bullish MACD signal. Recent trading has carved out support near $12.71 and resistance around $17.15.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 145.1% above the current quote. Revenue is contracting at 50.0%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 70.8%, a beta of 1.74 and a maximum drawdown of 69.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 145.1% above the current quote. Revenue is contracting at 50.0%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 70.8%, a beta of 1.74 and a maximum drawdown of 69.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Top Market Events
SOUTH SAN FRANCISCO, Calif. AP — SOUTH SAN FRANCISCO, Calif. AP — Lyell Immunopharma Inc. LYEL on Thursday reported...A required part of this site couldn’t load.<?xml encoding="utf-8" ? Top Wall Street analysts changed their outlook on these top names. For a complete view of all...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 20.42
- MACD momentum is positive
- 30-day price change of +15.3%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 20.42
- Analyst targets imply +145.1% versus the current price
- 30-day volatility of 70.8%
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +145.1% versus the current price
- Negative return on equity of -93.3%
- Revenue contracting at -50.0%
Key Metrics & Analysis
Financial Health
Revenue Growth-50.00%
P/E Ratio-2.4
ROE-93.28%
ROA-34.18%
Debt/Equity19.93
P/B Ratio1.5
Op. Cash Flow$-133260000
Free Cash Flow$-72809128
Industry P/E31.2
Technical Analysis
TrendNeutral
RSI57.5
Support$12.71
Resistance$17.15
MA 20$14.29
MA 50$13.75
MA 200$20.42
MACDBullish
VolumeDecreasing
Fear & Greed Index93.63
Valuation
Target Price$37.88
Upside/Downside145.15%
GradeFair
TypeBlend
Risk Assessment
Beta1.74
Volatility70.84%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.